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Abstract: Bcl-3 is a member of the IκB family of proteins and an important regulator of Nuclear
Factor (NF)-κB activity. The ability of Bcl-3 to bind and regulate specific NF-κB dimers has been
studied in great depth, but its physiological roles in vivo are still not fully understood. It is, however,
becoming clear that Bcl-3 is essential for the proper development, survival and activity of adaptive
immune cells. Bcl-3 dysregulation can be observed in a number of autoimmune pathologies, and
Bcl3-deficient animals are more susceptible to bacterial and parasitic infection. This review will
describe our current understanding of the roles played by Bcl-3 in the development and regulation of
the adaptive immune response, including lymphoid organogenesis, immune tolerance, lymphocyte
function and dendritic cell biology.
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1. NF-κB
The NF-κB family of transcription factors control the transcription of hundreds of genes
and regulate many key biological processes [1]. The majority of NF-κB target genes encode
immunomodulatory proteins, including cytokines [2–4], chemokines [5], and proteins involved in
the presentation of antigen to immune cells (www.nf-kb.org). Consequently, NF-κB is essential for
the development of the immune system and the induction of successful immunity [6–8], playing
indispensable roles in both the initiation and contraction of responses. NF-κB is therefore widely
considered to be a master regulator of the immune response.
NF-κB is a heterogeneous collection of homo- and heterodimers, with five proteins making up the
mammalian NF-κB family: p50, p52, p65 (RelA), c-Rel, and RelB. All share a conserved ~300 amino-acid
N-terminal Rel homology domain, which enables these NF-κB subunits to dimerise, localize to the
nucleus, and bind DNA [9]. p50 and p52 differ from the other NF-κB subunits in that they are
synthesized as large precursor proteins (p105 and p100, respectively) that must be processed by
the proteasome to generate mature subunits. The p100 and p105 precursors also play important
regulatory functions in the activation of NF-κB dimers via their C terminal ankyrin repeat domains
(see below). Functional p50 and p52 lack the C-terminal transactivation domain found in the other
NF-κB subunits. Consequently, p50 and p52 homodimers do not possess intrinsic transactivational
activity [10], and are generally considered to be repressors of gene transcription. However, p50 and
p52 can also hetero-dimerise with other NF-κB subunits, with the resulting heterodimers able to
activate transcription.
Two separate signaling pathways result in the activation of distinct dimeric NF-κB species,
leading to different biological outcomes. Activation of the classical (or canonical) pathway results
predominantly in the nuclear translocation of dimers containing c-Rel, p65 and/or p50. This pathway
is primarily involved in mounting effective immune responses, and contributes to the control of
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cell proliferation and survival. The second pathway is the non-canonical, or alternative pathway.
Activation of the non-canonical pathway is slower than that of the classical pathway, and centres on the
activation of the RelB and p52 subunits, controlling genes important in the regulation of homeostatic
processes [11]. It occurs downstream of a discrete group of receptors belonging to the tumor necrosis
factor receptor superfamily, including the lymphotoxin-β receptor, CD40, and the B-cell activating
factor (BAFF) receptor. It is worth noting, however, that certain receptors can activate both pathways,
and that considerable crosstalk exists between the signaling pathways [12].
The aberrant activation of NF-κB-mediated transcription is associated with various pathologies,
and can inflict severe damage to host tissues. As such, the regulation of NF-κB activity is essential, and
tightly controlled [13]. The principal means of restraining NF-κB activation is through the interaction
of NF-κB dimers with inhibitor of κB (IκB) proteins. The IκB family share a homologous central
domain comprised of 5–7 ankyrin repeats, which mediate their interactions with NF-κB dimers [14].
These proteins can be further classified into three subfamilies: the prototypical IκBs (IκBα, IκBβ,
and IκBε); the atypical IκBs (Bcl-3 [15], IκBNS [16], IκBζ [17] and IκBη [18]); and the p50 and p52
precursors, p105 and p100, respectively. The prototypical IκB molecules, along with p105 and p100,
interact with NF-κB dimers in the cytoplasm, inhibiting their translocation to the nucleus. On receipt
of an activatory stimulus, ubiquitin-dependent degradation of these IκB proteins occurs, liberating
active NF-κB dimers, which translocate into the nucleus and can then bind DNA target sequences.
The atypical IκB molecules, in contrast, are not degraded following NF-κB pathway activation and
reside primarily in the nucleus where they interact with NF-κB dimers to regulate transcription. This
modulation of NF-κB-dependent transcriptional programs is context-dependent, occurring in response
to specific stimuli received by the cell, and is essential for successful, controlled immune responses.
2. Bcl-3
The most extensively studied atypical IκB molecule, Bcl-3, was first identified as a putative
proto-oncogene. Cloning of chromosomal breakpoints found in chronic lymphocytic leukemia cells
demonstrated that the t(14;19) chromosomal translocation results in the juxtaposition of the BCL3
gene with the immunoglobulin (Ig) heavy locus leading to the overexpression of Bcl-3 in leukemic
cells [19–21]. Bcl-3 overexpression is also associated with a number of cancers that do not harbor
BCL3-associated translocations, including classical Hodgkin’s and peripheral T-cell lymphoma [22],
chronic lymphocytic leukemia [23], adult T cell leukemia [24], and certain solid tumors [25,26].
The Bcl-3 protein contains a central domain comprised of 7 ankyrin-repeats, flanked by a
proline-rich N terminal region and a serine/proline-rich C terminal region [27]. All IκB proteins contain
ankyrin-repeat domains, and the structural similarity between this region of Bcl-3 and previously
identified IκB molecules led to the prediction that Bcl-3 would exhibit NF-κB-regulatory functions.
Indeed, further studies identified Bcl-3 as an IκB protein [15,28,29] and demonstrated its ability to
interact with the p50 and p52 subunits of NF-κB via its ankyrin repeat domain [15,30–32]. Early reports,
however, disagreed on the precise role of Bcl-3 within the NF-κB pathways, and it was proposed that
Bcl-3 was able to: (i) block the nuclear translocation of p50 [33,34]; (ii) inhibit DNA-binding of p50
homo- and heterodimers [30,32,33]; (iii) limit p50-mediated NF-κB repression [31]; (iv) remove bound
p50-containing dimers from DNA [35]; (v) induce cytoplasmic activation of p50 [34]; and (vi) directly
transactivate genes when complexed with p50 [27,36] or p52 [37]. Nonetheless, it is now generally
accepted that Bcl-3 regulates classical and non-canonical NF-κB-dependent gene transcription through
selective interaction with homodimers of p50 and p52 [28,30,32,38], without inhibiting DNA-binding.
In fact, it has been shown in thymocytes that Bcl-3 enhances binding of p50 homodimers to NF-κB
target sites in DNA [39]. Additionally, studies using bone marrow-derived macrophages demonstrate
that Bcl-3 stabilizes DNA-bound p50 homodimers through the inhibition of p50 ubiquitination and
proteasomal degradation [40]. In response to Toll-like receptor and tumor necrosis factor (TNF)
receptor signalling, κB target sites in the DNA can become blocked by Bcl-3-stabilized p50 homodimers,
preventing transcriptionally active dimers from binding and driving gene transcription [40]. In this
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way, Bcl-3 is able to limit the pro-inflammatory transcriptional programs initiated by certain classical
pathway stimuli [40,41]. However, Bcl-3-mediated suppression of the classical pathway is likely to be
context and/or stimulus dependent, and further work is still needed to fully understand the functional
consequences of the interaction of Bcl-3 with p50 homodimers.
The role of Bcl-3 in the regulation of p52 homodimers is even less clear. Evidence points
to a requirement of Bcl-3 for optimal non-canonical signaling [42], with the phenotypes of Bcl3
knockout mice (Bcl3´{´) echoing those of mice with defects in specific non-canonical NF-κB signaling
components [43,44]. Interestingly, Bcl-3 has also been reported to act as an adaptor molecule, capable
of recruiting a number of nuclear coactivator and corepressor complexes to p50/52 homodimers [45],
and itself contains two transactivating domains that are able to directly stimulate transcription when
bound to homodimers of p50 or p52 [27,36]. Clearly, these non-IκB activities of Bcl-3 add a further
layer of complexity to the potential functions of this protein, especially in the context of Bcl-3:p50
homodimer interaction. Bcl-3 has a predominantly repressive role in the classical pathway of NF-κB
activation, however under certain circumstances it may also act to enhance the transcription of specific
genes [46]. The molecular basis for the dual function of Bcl-3 in the classical pathway, and the signals
that control its inhibitory versus activatory potential, are still not fully understood.
Unravelling the molecular details of Bcl-3 is further complicated by its numerous post-translational
modifications (PTMs). Bcl-3 is a highly phosphorylated protein [27,32,39,47], with phosphorylation
at specific sites shown to be crucial for its activity in certain contexts. Phosphorylation of Bcl-3 by
the protein kinase GSK3 selectively regulates the ability of Bcl-3 to control transcription of a subset of
NF-κB target genes [37]. Microarray analysis of NIH3T3 cells transfected with either wild-type Bcl-3 or
a Bcl-3 mutant lacking GSK phosphorylation sites demonstrated the differential regulation of Slpi, Cxcl1,
Ifi205 and Cypibi by phosphorylated and un-phosphorylated Bcl-3 [37]. Hypo-phosphorylated Bcl-3 has
been shown to have increased interaction with transcriptional corepressors [37], and studies looking at
nuclear extracts from Bcl-3 transgenic thymocytes have shown that Bcl-3 de-phosphorylation lessens
its ability to enhance DNA:p50 homodimer binding [39]. Ubiquitination of Bcl-3 also plays a key
role in its activation by regulating intracellular Bcl-3 localization. Although primarily located in the
nucleus, in certain cell types inactive Bcl-3 localizes to the cytoplasm [48,49]. Cytoplasmic Bcl-3 requires
K63-linked polyubiquitination in order to translocate to the nucleus. The de-ubiquitinase CYLD has
been shown to control Bcl-3 localization in keratinocytes through the removal of these polyubiquitin
chains, preventing nuclear accumulation of Bcl-3 and consequently, Bcl-3-mediated regulation of gene
transcription [50]. It is not yet fully understood how these, and other, PTMs affect Bcl-3 function, but
they may act as a route through which cellular responses can be precisely manipulated, depending on
the particular cell type and stimulus received.
Although the molecular characterization of Bcl-3 has revealed several important mechanisms
through which NF-κB activity may be controlled, much is still to be uncovered. Along with work aimed
at defining the molecular details of Bcl-3, many studies have focused on understanding the cellular
functions of Bcl-3 in vivo. Bcl-3’s involvement in the immune system has been examined in some depth,
and this review will focus on the adaptive immune response, exploring the current knowledge in this
field (summarized in Figure 1). It is worth noting that Bcl-3 has also been implicated in the regulation
of multiple innate immune cell populations, including macrophages [40,51–53], neutrophils [54], mast
cells [55], and certain stromal cells [56], however these are outwith the scope of this review, and so will
not be discussed further.
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development of lymphocytes within SLOs; (B) Bcl-3 is crucial to the regulation of B cell proliferative 
responses, effective germinal center (GC) formation and the production of class-switched antibodies; 
(C) Bcl-3 is involved in the differentiation and development of TH cell subsets in the periphery, acts 
as a survival factor in activated T cells, and has been implicated in the induction of anergy in CD4+ T 
cells; (D) Bcl-3 promotes DC survival, and enhances successful antigen presentation and T cell 
priming by DCs. 
To aid readers who are not immunologists, we will first provide an overview of the adaptive 
immune system in the hope that this will make our subsequent descriptions of Bcl-3 function more 
broadly accessible. Those with an immunology background may wish to skip this part of the review 
and go straight to Section 4. 
Figure 1. Bcl-3 is involved in the development and function of the adaptive immune response.
(A) Bcl-3 is an important factor in the development of the adaptive immune system, with roles in the
organogenesis of secondary lymphoid organs (SLOs), such as Peyer’s patches, the correct formation of
splenic microarchitecture, the induction of central T cell tolerance in the thymus, and the development
of lymphocytes within SLOs; (B) Bcl-3 is crucial to the regulation of B cell proliferative responses,
effective germinal center (GC) formation and the production of class-switched antibodies; (C) Bcl-3 is
involved in the differentiation and development of TH cell subsets in the periphery, acts as a survival
factor in activated T cells, and has been implicated in the induction of anergy in CD4+ T cells; (D) Bcl-3
promotes DC survival, and enhances successful antigen presentation and T cell priming by DCs.
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To aid readers who are not immunologists, we will first provide an overview of the adaptive
immune system in the hope that this will make our subsequent descriptions of Bcl-3 function more
broadly accessible. Those with an immunology background may wish to skip this part of the review
and go straight to Section 4.
3. The Adaptive Immune Response
The immune system is comprised of two interacting branches: the innate immune system,
providing rapid first line defense against infection; and the adaptive immune system, which offers
a slower, but more tailored response and generates immunological memory. Adaptive immune
responses require the presentation of antigens (Ags) to lymphocytes expressing specific cell-surface
Ag receptors. There are two major lymphocyte populations: T cells and B cells. Each lymphocyte
carries a unique Ag receptor, referred to as the T Cell Receptor (TCR) or the B Cell Receptor (BCR), and
consequently, lymphocyte populations are capable of recognizing an enormous number of Ags.
Lymphocytes develop from haemopoietic stem cells in the bone marrow. T cells undergo further
development in the thymus, while B cells complete their maturation in the spleen. During development,
each lymphocyte expresses a randomly generated TCR or BCR on its surface. Many of these are
non-functional or recognize self-Ags. To eliminate cells carrying such receptors, immature lymphocytes
undergo a screening process, referred to as central tolerance. This occurs in the bone marrow for B
cells [57], and in the thymus for T cells [58], and is important as the release of self-reactive lymphocytes
into the periphery can lead to the development of autoimmunity. During T cell development, a
specialized population of immunosuppressive regulatory T cells (Tregs) are also generated, called
natural Tregs, which can suppress autoimmunity and regulate adaptive immune responses [59]. These
developmental processes generate the pool of circulating “naïve” lymphocytes. Naïve T cells express
either the CD4 co-receptor, and are referred to as CD4+ T cells or T helper cells, or the CD8 co-receptor,
in which case they are called CD8+ T cells or cytotoxic T cells [60]. Most naïve B cells are known as
follicular B cells (FO B cells), but two rare populations, marginal zone B cells (MZ B cells) and B1 B
cells, are also found in mice.
To participate in adaptive immunity, naïve lymphocytes must encounter their cognate Ag. This
occurs primarily in the specialised microenvironments of secondary lymphoid organs (SLOs) (e.g.,
spleen, lymph nodes (LNs), tonsils, and intestinal Peyer’s patches). Each SLO efficiently captures and
presents Ags from particular extracellular fluids: for example, the spleen filters blood while LNs trap
Ags in lymph. In SLOs, B cells and T cells segregate into specific microanatomical niches containing
distinct Ag-presenting cells and stromal cells. FO B cells reside in follicles, MZ B cells in the splenic
marginal zone, and T cells in T cell areas. It is here that naïve lymphocytes encounter Ag, and where
adaptive immune responses are initiated and predominantly regulated.
Naïve T cells respond to Ag presented on major histocompatibility complex (MHC) proteins by
dendritic cells (DCs) in the periphery [61]. DCs also provide information to Ag-specific T cells that
dictate their subsequent fate. Clearly it is not desirable for T cells to respond to self-Ags or harmless Ags
in food or commensal bacteria, so these Ags are presented in such a way that any T cells that recognise
them are either destroyed, converted into induced Tregs, or made anergic (i.e., become functionally
unresponsiveness to Ag). This process is referred to as peripheral tolerance, and is a second layer of T
cell regulation, following central tolerance in the thymus. In contrast, it is essential that T cells that
recognise Ag from a potentially harmful pathogen are instructed to contribute to immune defence.
DCs presenting such Ags send signals to T cells that drive their proliferation (to increase the number
of Ag-specific T cells), and push them to develop functional properties that aid pathogen clearance.
CD8+ T cells develop the ability to kill malignant or infected cells, while activated CD4+ T cells can
differentiate into a number of different types of T helper cell (e.g., TH1, TH2, TH17, or TFH) [62]. Each
T helper cell subset expresses a characteristic repertoire of immunomodulatory cytokines and can
influence specific aspects of the immune response, such as inflammation, cytotoxicity, or antibody
(Ab) production by B cells (see below). Moreover, some activated T cells develop into memory T cells
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that are far more responsive to Ag than naïve T cells, and mount rapid and robust responses when
Ag-bearing pathogens are encountered again. Multiple checks and balances exist to ensure that T cell
responses are controlled and resolved: Tregs play a critical role by suppressing activated T cells via
direct cell contact and immunosuppressive cytokine release.
The principal purpose of B cells is to develop into Ab-secreting cells (ASCs). B cells can be
activated by cognate Ag in several ways, each leading to their proliferation and differentiation into
ASCs. However, without “help” from follicular T helper cells (TFH), these ASCs are short-lived, and
the Ab they release has relatively low affinity for Ag and limited effector functions. To receive help,
B cells present peptides derived from their cognate Ag on MHC to TFH cells previously activated
by the same Ag presented on MHC by DCs. TFH cells support the development of structures in
SLOs called Germinal Centers (GCs) in which activated B cells undergo further differentiation and
selection [63]. The ASCs formed in GCs have an extended lifespan and produce high affinity Abs, and,
because of a process called “class-switching”, these Abs have a broader range of effector functions.
GCs also generate memory B cells, which rapidly produce high affinity Abs when their cognate
Ag is re-encountered. Since powerful B cell responses depend on activated T cells, and T cells are
subject to the regulation described above, unwelcome and potentially damaging B cell responses are
indirectly avoided.
In summary, the adaptive immune system, via the coordinated interaction of DCs, T cells and
B cells in specialised tissues, delivers a flexible controlled response to pathogen-associated Ags and
generates memory cells for lifelong protection. Although the existence of autoimmunity demonstrates
its fallibility, adaptive immunity is essential for human life and the target of effective vaccines.
4. Bcl-3 Involvement in Central Tolerance
Medullary thymic epithelial cells (mTECs) are stromal cells in the thymus critical for effective
central tolerance [64]: they express and present Ags found elsewhere in the body. T cells are exposed
to these Ags whilst in the thymus, and any potentially auto-reactive T cells that recognize these Ags
are deleted [65]. Defective mTEC development or function can lead to multiorgan inflammation
due to the release of auto-reactive T cells into the periphery. Mice deficient in either Nfkb2 (which
encodes p52/p100) or Bcl3 demonstrate no overt autoimmune pathology, however mice lacking
both genes (Nfkb2´{´Bcl3´{´) spontaneously develop inflammatory infiltrates in multiple organs
and die within four weeks of birth [43]. While natural Treg development and function appears
normal in Nfkb2´{´Bcl3´{´ mice, these animals have increased numbers of activated auto-reactive T
cells [43]. Moreover, autoimmune pathology can be induced by transferring Nfkb2´{´Bcl3´{´ T cells
into Rag1´{´ mice (which do not produce their own T or B cells) [43]. Thus, auto-reactive T cells drive
inflammation in Nfkb2´{´Bcl3´{´ animals, pointing to a defect in central tolerance. Studies using
bone-marrow chimeras indicate that stromal cells, rather than haemopoietic cells, are necessary and
sufficient for the development of autoimmunity in these mice. They have a highly abnormal thymus,
which has virtually disappeared by four weeks of age. Moreover, mTEC development is defective and
this is likely to be major reason why these mice are unable to successfully eliminate auto-reactive T
cells. Although the molecular basis for this defect has not been precisely defined, Nfkb2 deficiency
removes p52, so the impact of Bcl3 deletion in mice lacking Nfkb2 is likely to be due to alterations in
classical NF-κB signalling stemming from the loss of p50/Bcl-3 interactions. Based on these findings, it
appears that activation of both NF-κB pathways is required to develop fully functional mTEC and/or
other stromal cells involved in central tolerance, although further studies are required to determine
precisely how the NF-κB pathways are working in these cells.
5. The Role of Bcl-3 in SLO Development
It has long been known that NF-κB plays a critical role in the development of SLOs [44], and so
it is not surprising that Bcl3 deficiency also leads to developmental defects in SLOs. Bcl3´{´ mice
have impaired Peyer’s patch development, as well as disruptions in their splenic and LN architecture.
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Peyer’s patches are macroscopic aggregated lymphoid follicles found at regular intervals along the
length of the small intestine. Large B cell follicles sit adjacent to a T cell-rich area and are separated from
specialized follicle-associated epithelium by the DC-rich sub-epithelial dome (SED), which captures
Ags delivered from the gut lumen [66]. Compared to wild-type mice, Peyer’s patches in Bcl3´{´
mice are smaller and less abundant, although a far stronger phenotype is seen in mice lacking either
Nfkb1 (which encodes p50/p105) or Nfkb2 [38]. The Peyer’s patches that do develop in Bcl3´{´ mice
have enlarged T cell areas and small follicles, which contain fewer follicular dendritic cells (FDCs), an
antigen-presenting stromal cell present in SLO follicles [38]. The distribution of DCs in the SED is also
abnormal in these animals, and there is an increase in the number of M cells, specialized epithelial cells
that transport Ags from the gut lumen to the SED [38]. Interestingly, the expression of the chemokines
CXCL13 and CCL20, which drive the recruitment of cells to follicles and SED, respectively, are highly
dependent on p100/p52 and Bcl-3 [38], which may explain the defects in the Peyer’s patches of Bcl3´{´
mice. This could also account for the reduction in Peyer’s patch number, as CXCL13 plays a critical
role in inducing Peyer’s patch formation through its ability to recruit lymphoid tissue inducer cells to
the wall of the small intestine during embryogenesis [67,68].
The lymph nodes of Bcl3´{´ mice are reported to be hypoplastic and, like the Peyer’s patches,
contain fewer B cells. Additionally, the spleens of these animals contains abnormally small follicles
containing fewer B cells, FDCs and GCs [44,69,70]. The non-canonical NF-κB pathway is known to
be crucial for the correct formation and function of SLOs, and the phenotypic similarities between
Nfkb2´{´ mice and Bcl3´{´ mice have led to the proposition that Bcl-3 enhances p52-mediated
transcription during lymphoid organogenesis. However, as in the thymus, Bcl3 deficiency substantially
enhances SLO phenotypes in Nfkb2´{´ mice: while Nfkb2´{´ and Bcl3´{´ mice have lymph nodes,
Nfkb2´{´Bcl3´{´ mice completely lack these organs [71]. As such, it seems likely that Bcl3 deficiency
leads to alterations in p50 function or regulation during embryogenesis. However, these observations
do not exclude the possibility that SLO defects in mice lacking only Bcl3 are caused, at least in part, by
dysregulation of the non-canonical NF-κB pathway.
6. The Role of Bcl-3 in B Cell Development and Function
The most obvious phenotype in Bcl3´{´ animals is the reduction in the number of B cells in their
SLOs. Interestingly, it is actually only FO B cell numbers that are reduced: these animals have more MZ
B cells than wild-type mice [71]. MZ B cells are a sessile population of cells that reside in the splenic
MZ and participate in T cell-independent B cell responses to blood-borne Ag/pathogens [72]. In mice,
the final steps of B cell development occur in the spleen, with newly arriving bone marrow-derived
immature B cells passing through a series of transitional stages before differentiating into either FO or
MZ B cells. Cell fate decisions depend on the strength of specific intracellular signals, and the deletion
of genes that regulate these signals often alters the FO/MZ B cell ratio [73]. The canonical NF-κB
pathway transduces one of these key fate-determining signals, and so the B cell phenotype in Bcl3´{´
mice likely reflects a change in the activity of this pathway. Indeed, in support of this hypothesis, Zhang
and colleagues have demonstrated that this phenotype is due to a B cell-autonomous defect, rather
than an aberration in the splenic stromal cell compartment [71]. However, the molecular mechanisms
by which Bcl-3 regulates MZ B cell development remain to be defined, although a modest increase in
integrin expression by Bcl3´{´ MZ B cells might aid their retention in the MZ and contribute to their
increased abundance in the spleen [71]. Also, it is worth noting that the splenic MZ of Bcl3´{´ mice
contains fewer macrophages than wild-type mice and has certain molecular defects, including reduced
expression of MAdCAM-1 by sinus-lining cells and lower levels of the basement membrane protein
laminin β-2 adjacent to these cells [69,70]. Again, the molecular basis for these defects are not known,
and it is not clear whether these features contribute to, or are a consequence of, the accumulation of
MZ B cells in these animals.
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Several different mouse strains have been generated that over-express Bcl-3 in their B cell
compartments. These mice have been used to examine the oncogenic functions of Bcl-3, but their
immunological phenotypes are also of interest. Eµ-BCL3 mice express a human BCL3 transgene in
both their T and B cells [74], while two recently-developed strains, including Bcl-3BOE mice, carry a B
cell-restricted mouse Bcl3 transgene [71,75]. In all of these strains there is an expansion of the B cell
compartment, with mature FO B cells accumulating in multiple organs, including the spleen, LNs,
bone marrow and peritoneal cavity. Despite this, these animals do not develop lymphoid malignancies,
indicating that Bcl-3 over-expression alone is not sufficient to drive lymphomagenesis. Strikingly,
MZ B cells are virtually absent from mice expressing transgenic Bcl3 only in B cells [71,75], providing
further evidence that the strength of NF-κB signals controls cell fate decisions in developing B cells in
the spleen. Bcl-3BOE mice are also reported to lack MZ B cell precursors and to have fewer B1 B cells in
their peritoneal cavity. The increased number of FO B cells in these transgenic mice may be caused
by this skewed differentiation, pushing more B cell precursors into the FO B cell pool, but it is also
possible that Bcl-3 over-expression alters FO B cell dependence on B cell survival factors, such as BAFF.
Another striking feature of SLOs in Bcl3´{´ mice is the virtual absence of GCs under steady-state
conditions [38,69], and GCs are poorly induced by infection or immunization with experimental
model Ags [69,70,76]. As a consequence, these mice have defects in the generation of certain types
of “class-switched” Abs that are produced by ASCs generated in GCs. For example, after influenza
virus infection, Bcl3´{´ mice have lower levels of class-switched anti-virus IgG2a Abs, but normal
levels of IgM, a type of Ab that is generated independently of GCs and does not require T cell help [69].
Similarly, compared to wild type controls, Bcl3´{´ mice challenged with heat-killed Streptococcus
pneumoniae have lower serum levels of class-switched Abs specific for the bacteria [76]. Protection
from S pneumoniae infection requires an effective Ab response involving class-switched Abs, and so it
is perhaps not surprising that Bcl3´{´ mice show increased susceptibility to the development of sepsis
after infection with live S pneumoniae [76]. The precise cellular basis for the GC defect in Bcl3´{´ mice
is not clear. However, it is notable that these mice fail to develop dense FDC networks in the follicles
after challenge. Instead their FDCs are aberrantly dispersed throughout the white pulp, and their
ability to capture Ag is compromised [70]. FDCs are key cells involved in Ag presentation to FO B
cells, and they play critical roles in the formation and function of GCs. The FDC phenotype in Bcl3´{´
mice appears to be a milder form of that seen in Nfkb2´{´ mice, in which the FDC network is more
substantially disrupted: these mice fail to develop any GCs or elicit effective B cell responses [70,77,78].
However, it is not clear if, or how, Bcl-3 influences signalling through the classical or non-canonical
NF-κB pathways in FDCs.
The responses of B cells expressing Bcl3/BCL3 transgenes vary depending on which particular
transgenic strain is analysed. When activated by BCR cross-linking in vitro, Eµ-BCL3 splenocytes
proliferate more rapidly than wild-type splenocytes. However, when Bcl-3BOE B cells are activated in a
similar way they proliferate less well than wild-type B cells, while B cells from another strain with a B
cell-specific Bcl3 transgene behave like wild-type B cells [71]. These differences are difficult to explain,
although BCL3 transgene expression in T cells likely contributes to responses in Eµ-BCL3 splenocyte
cultures: when these cells are removed the enhanced proliferative response to BCR cross-linking
is abrogated. Unchallenged Eµ-BCL3 mice develop increased numbers of GCs, and their serum
carries elevated levels of some class-switched Abs (IgG1 and IgA) [74]. However, Bcl-3BOE mice have
normal IgG1 levels, a reduced number of GCs, and dampened Ab responses after immunization with
T cell-dependent Ags [75]. Again, these differences between strains may be caused by the expression
of the BCL3 transgene by T cells in Eµ-BCL3 mice. What is notable however about the Bcl-3BOE mice is
that despite having increased numbers of FO B cells, these cells appear less able to participate in GC
formation. Bcl-3BOE mice also show defective production of IgM and IgG3 in response to immunization
with T cell-independent Ag. This is likely due to the paucity of MZ and B1 B cells in these mice, as
these B cell subsets are major contributors to T cell-independent Ab responses.
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Collectively, these studies demonstrate that endogenous Bcl-3 is critical for the development of B
cells and for optimal B cell responses, and that Bcl-3 over-expression can substantially influence B cell
behavior. This is presumably because Bcl-3 regulates NF-κB signaling in B cells and/or other cell types
critical for B cell function, such as FDCs and T cells. However, the precise molecular mechanisms are
not fully understood, and further work is needed to elucidate the details of Bcl-3 function in this key
population of adaptive immune cells.
7. The Role of Bcl-3 in T Cells
In addition to its role in central T cell tolerance, Bcl-3 has been shown to be involved in the
generation of differentiated CD4+ TH cells. In vitro studies have shown that Bcl3 deficiency in T cells
results in impaired TH2 differentiation due to a defect in the expression of GATA-3 [46], the master
transcription factor for TH2 cell differentiation. Molecular studies have shown that Bcl-3 and p50 are
able to bind to κB-like sites within the gata3 promoter, suggesting Bcl-3 may be able to initiate direct
transactivation of gata3 [46]. These results, together with findings demonstrating a central role for RelB
in TH1 cell differentiation, have led to the proposition that the balance of Bcl-3 and RelB in the nucleus
might, to some extent, determine whether a CD4+ T cell differentiates into a TH1 or a TH2 cell. These
studies however, do not exclude other potential mechanistic explanations, such as the recruitment of
co-activators to gene promoter regions by Bcl-3, and further investigations are needed to fully clarify
Bcl-3’s molecular function in TH2 cell differentiation. TH2 populations present in Bcl3´{´ mice also
exhibit diminished production of cytokines characteristic for TH2 cells, i.e., IL-4, IL-5 and IL-13 [46].
These findings are not surprising considering the reduced expression of GATA-3, as this transcription
factor is known to be responsible for the production of these cytokines [79].
Several studies have reported that the in vitro differentiation of naïve T cells to TH1 [46,80] or
TH17 cells [80] is not altered by the absence of Bcl-3. Interestingly, however, it has recently been shown
that Bcl-3 suppresses the conversion of IFN-γ-producing TH1 cells into TH17 cells in vivo [80]. These
experiments were performed using a model of colitis induced by transferring CD4+CD25´ T cells
into Rag1´{´ mice. Recipients of wild-type T cells succumb to colitis 6–7 weeks after transfer due to
the development of IFN-γ+ TH1 cells, but remarkably, when T cells from Bcl3´{´ mice were used the
recipients remained healthy. When donor T cells were recovered from the spleen, mesenteric LN and
colon 7 weeks after transfer, far fewer of the Bcl3´{´ T cells were IFN-γ+ TH1 cells, and there was
a corresponding increase in less colitogenic IL-17-producing TH17 cells. This phenotypic shift was
particularly prominent in the mesenteric LN and colon. Conversion to TH17 cells was also able to
limit the pathogenicity of Bcl3´{´ TH1 cells in experimental autoimmune encephalomyelitis [80], a
mouse model of multiple sclerosis. An increase in expression of RORγt, a key transcription factor that
controls TH17 differentiation [81], and a concomitant decrease in expression of T-bet, the TH1 master
regulator [82], was found in the IL-17-producing cells, confirming their conversion to the TH17 lineage.
Enforced over-expression of RORγt is able to make TH1 cells develop a TH17 cell phenotype [80], and
there is evidence that Bcl-3 controls TH cell plasticity by suppressing RORγt production. The Rorc gene
encodes the RORγt protein, and its promoter contains NF-κB-binding sites that have been shown to
interact with the classical pathway subunits c-Rel, p50 and p65 [80,83]. Binding of c-Rel and p65 to
these sites induces Rorc expression, RORγt production, and TH17 differentiation [83]. Rorc expression
is inhibited in TH1 and TH17 cells generated from mice expressing a T cell-specific Bcl3 transgene, and,
in the TH1 cells, Bcl-3 protein encoded by the transgene is bound to regions of the Rorc promoter that
contain NF-κB-binding sites [80]. Moreover, Bcl3 deficiency results in the increased presence of c-Rel
on the Rorc promoter in TH1 cells generated in vitro. Thus, in TH1 cells, Bcl-3-mediated stabilization
of inhibitory p50 homodimers on NF-κB-binding sites in the Rorc promoter might be responsible for
restricting RORγt production, thereby stabilizing the TH1 cell phenotype and restricting conversion to
TH17 cells.
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A role for Bcl-3 in the development of TFH cells has also recently been proposed [84]. In a study by
Meguro and colleagues [84], mouse CD4+ T cells activated in vitro and transduced with Bcl3-containing
retroviruses were found to express more Bcl6, a master regulator of TFH cell differentiation [85],
compared to control samples. Bcl3 retroviruses increased the expression of numerous genes, although
other TFH cell markers, such as Cxcr5, Icos and Ascl-2, were not among them. The Bcl3 retrovirus also
enhanced the generation of TFH cells in mice. Conversely, under TFH cell-inducing conditions in vitro,
reducing the level of endogenous Bcl-3 decreased the number of murine T cells expressing IL-21, a
signature cytokine of TFH cells, and suppressed the expression of BCL6 by human T cells. This study
also provides evidence that Bcl-3 can associate with the promoters of the Bcl6 and Il21 genes, and,
in cell lines, can enhance expression of reporter genes controlled by the Bcl6 or Il21 promoters. This
suggests that Bcl-3 is directly involved in the transcriptional activation of these TFH genes, although
the mechanisms by which it achieves this regulation remain to be defined [84].
In addition to its effect on TH cell differentiation, Bcl-3 has also been reported to act as a survival
factor for activated T cells [86–88]. These findings are perhaps unsurprising, as it has been known
for some time that NF-κB plays a central role in ensuring lymphocyte survival. Ectopic expression of
Bcl-3 is able to enhance T cell survival after activation [86,87], and increased cell death is apparent in
populations of activated Bcl3´{´ T cells containing both CD4+ and CD8+ cells [87]. In this setting, the
pro-survival function of Bcl-3 was attributed to its ability to block activation of Bim [87], a pro-apoptotic
member of the Bcl-2 protein family, although the molecular mechanisms at work are not clear. CD8+ T
cells require IL-12 signals at the time of Ag encounter in order to undergo clonal expansion and become
fully activated [89]. Bcl-3 expression is up-regulated in CD8+ T cells in response to IL-12 stimulation,
and Bcl3-deficient CD8+ T cells are unable to respond to survival signals elicited by IL-12 [90]. It is
not known how Bcl-3 controls T cell survival, or how it is induced in activated T cells, but it has been
postulated that cytokines produced by DCs activate the transcription factor AP-1, which is known to
be involved in the induction of Bcl3 transcription [91].
Bcl-3 has also been implicated in the control of CD4+ T cell anergy during peripheral tolerance.
Bcl-3 expression is specifically induced in anergic CD4+ T cells and inhibits their production of
IL-2 [92]. IL-2 is a potent T cell growth factor that is produced by activated T cells, initiating population
expansion and differentiation into effector cells. In this context, Bcl-3 is thought to enhance the binding
of p50 homodimers to the IL-2 promoter region, altering the composition of NF-κB dimers in the
nuclei of T cells and inhibiting NF-κB-dependent transcription [92]. Bcl-3 has also been shown to
inhibit NF-κB-dependent transcription in T cells in response to specific cytokines (IL-4 and IL-9) [55],
demonstrating yet another layer of Bcl-3-mediated control of T cell responses.
Collectively, these studies reveal that Bcl-3 is a context-dependent regulator of T cell responses
that can affect the generation of differentiated TH cells, the stability of TH cell phenotypes, the survival
of activated CD4+ and CD8+ T cells, and the reinforcement of T cell anergy. Although much is
known about Bcl-3’s involvement in T cell development and function, the molecular mechanisms
underpinning these cellular functions are still being revealed, and it will be interesting to see how this
area of research develops in the future.
8. The Role of Bcl-3 in DC Development and Function
Although not considered adaptive immune cells in their own right, DCs are crucial to the initiation
of adaptive immune responses. As mentioned in section 3 above, DCs present Ags to naïve T cells
and direct their subsequent differentiation. Bcl-3 is highly expressed in mature DCs [93], and recent
work using mice with a DC-specific Bcl3 deletion (Bcl3∆DC mice) has demonstrated the requirement
of Bcl-3 for successful Ag presentation to CD4+ and CD8+ T cells by DCs, both in vitro and in vivo [94].
Moreover, Bcl3 over-expression in DCs enhances T cell priming and proliferation [94]. Bcl-3 contributes
to changes in the expression of surface molecules on mature DCs, altering the balance between
co-stimulatory and inhibitory factors in favour of activatory signals [94]. However, it is the ability of
Bcl-3 to promote DC survival that appears to be critical, allowing optimal DC:T cell interactions to
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occur, and thereby supporting successful T cell priming. The shortened life-span of activated Bcl3´{´
DCs may limit the duration of DC:T cell interactions and consequently prevent T cells from receiving
the activatory signals required for successful priming. When compared to equivalent cultures of wild
type DCs, Bcl3-deficient DCs show increased expression of pro-apoptotic genes after stimulation with
LPS [94]. This finding is likely to underpin the survival defect of these cells, however, it remains to be
determined if Bcl-3 is associated with the promoters of these genes in DCs and, if so, how this controls
their activity.
Another recent study has demonstrated that Bcl-3 can also modify cytokine production by
activated DCs [95]. Fucose-containing ligands found on extracellular pathogens bind to DC-SIGN, a
C-type lectin expressed by DCs. Signalling through DC-SIGN can repress the ability of activated DC to
express pro-inflammatory cytokines, including IL-6, IL-12, and IL-23, while enhancing their expression
of IL-10 and chemokines capable of attracting TH2 cells. During CD4+ T cell priming, this shifts
differentiation from the TH1 to the TH2 lineage. Interestingly, the regulation of cytokine/chemokine
expression in DCs by DC-SIGN ligands is dependent on Bcl-3-mediated modulation of NF-κB
dimer occupancy on cytokine promoters, with DC-SIGN signalling resulting in a shift towards p50
homodimers. This is achieved through the activation of IKK-ε by DC-SIGN, which leads to suppression
of CYLD, a deubiquitinase that removes ubiquitin from Bcl-3. As previously mentioned in section 2
above, ubiquitination of Bcl-3 aids its translocation to the nucleus [50]. Consequently, when CYLD is
suppressed, ubiquitinated Bcl-3 is able to translocate to the nucleus where it influences which NF-κB
dimers are present on cytokine promoters.
Sub-optimal T cell priming results in impaired adaptive immune responses, leaving the host
susceptible to infection. Further work by Tassi and colleagues has shown that Bcl3 expression by
DCs is vital for the effective clearance of Toxoplasma gondii infection [96]. T cell responses and IFN-γ
are critical for protection from this intracellular protozoan, and, unlike their wild-type counterparts,
Bcl3´{´ mice cannot control T gondii infection and die within 5 weeks of infection [69]. Remarkably,
Bcl3∆DC mice were as susceptible to T gondii infection as mice that lacked Bcl3 in all their cells [96].
Early innate responses to infection were maintained in these animals, but later adaptive responses were
compromised: their CD4+ and CD8+ T cells produced substantially less IFN-γ than wild-type controls
at a time during infection when this cytokine is known to be important for protective responses.
Although the impact of Bcl3 loss on DC biology was not specifically explored in this study, defects in
DC survival or changes in cytokine production similar to those discussed above could be responsible
for the effects observed.
Thus, not only does Bcl-3 control the behaviour of T and B cells during adaptive immune responses,
but it also has a key role in ensuring that Ags are presented to naïve T cells, and that T cell-dependent
adaptive immune responses are appropriately initiated.
9. Bcl-3 and Immunopathology
Since Bcl-3 influences the function of adaptive immune cells, it is perhaps unsurprising that
aberrant Bcl-3 expression has been associated with a range of immune dysfunctions. Altered Bcl-3
expression levels have been observed in several autoimmune diseases. A 2010 study identified
single-nucleotide polymorphisms in the BCL3 gene, which predicted reduced Bcl-3 protein expression,
as a likely risk factor for Crohn’s disease [97]. A more recent report, however, demonstrates that patients
with both Crohn’s disease and ulcerative colitis have elevated expression of BCL3 compared to healthy
individuals [98]. Work using the dextran-sodium sulfate (DSS) mouse model of colitis showed that
colitis was associated with a significant increase in Bcl3 expression, and that Bcl-3-deficiency provided
partial protection against disease development [98]. Bcl3´{´ mice demonstrated comparable levels of
immune cell infiltration and pro-inflammatory cytokine production compared to wild-type controls,
indicating that, in this context, Bcl-3 did not appear to be directly regulating inflammation. Instead,
Bcl-3 is thought to play a role in regulating intestinal epithelial cell turnover under inflammatory
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conditions, with the enhanced epithelial cell proliferation and regeneration present in Bcl3´{´ mice
after disease onset supporting this suggestion [98].
In contrast, Bcl3 deficiency has been shown to render mice more susceptible to autoimmune
diabetes [99]. The absence of Bcl3 appeared to have no effect on TH1 or TH2 responses, but it did result
in enhanced expression IL-17A, the TH17 signature cytokine, indicating that TH17 responses were
increased [99]. Susceptibility to diabetes is also affected by c-Rel-deficiency in mice, which confers
resistance to low-dose streptozotocin-induced diabetes [100], indicating that Bcl-3 may be influencing
diabetes susceptibility through its role in the classical pathway of NF-κB activation. This work also
identified Bcl-3 as a regulator of chemokine gene expression in diabetes, and suggested a possible role
for Bcl-3 in TH17 cell expansion and/or survival through an IL-23-dependent mechanism. This idea is
supported by the work discussed above regarding Bcl-3-mediated stabilization of TH1 cell phenotype
through the inhibition of RORγt expression [80]. In the absence of Bcl-3, the plasticity of TH1 cells is
increased, allowing for an enhanced conversion to TH17 cells in response to IL-23, and it is possible
that such alterations in the properties of diabetogenic T cells aid the development of diabetes.
A 2012 study focusing on the identification of biomarkers predictive for early rheumatoid arthritis
(RA) has revealed a correlation between BCL3 expression by circulating T cells and disease, with
BCL3 identified as one of twelve genes comprising a potential CD4+ T cell gene “signature” in RA
patients [101]. Similarly, DNA microarray analysis of CD4+ T cells from untreated RA patients and
healthy controls demonstrated an increased expression of BCL3 in those with RA [84]. BCL3 expression
decreased after successful treatment with tocilizumab (which blocks the IL-6 receptor), but not after
treatment with inhibitors of TNF or CD80/86 [84]. RA patients have elevated levels of circulating IL-6,
and this cytokine induces Bcl-3 expression in both mouse and human CD4+ T cells [84,102]. It has also
been proposed that elevated BCL3 reflects the increase in circulating TFH cells previously shown to
exist in RA patients, which correlates with disease activity [103,104]. Indeed, in RA patients, increased
expression of the TFH-associated genes CXCR5, ICOS and ASCL-2 correlated with elevated levels of
BCL3 expression and higher disease activity [84]. Perhaps, then, IL-6-driven BCL3 induction enhances
the development of TFH in RA.
10. Conclusions
Bcl-3 plays important roles in NF-κB regulation, able to either promote or inhibit NF-κB target
gene expression depending on the cell type and stimulus received. Expression of Bcl-3 is tightly
regulated, and aberrant expression of this IkB molecule results in a range of defects within the immune
compartment. Animals with a deficiency in Bcl-3 present with defects in the microarchitecture of
their secondary lymphoid organs and disrupted adaptive immune responses, resulting in increased
susceptibility to infection. Bcl-3 over-expression detrimentally alters the composition of both the B and
T cell compartments, with animals suffering lymphoproliferative disorders. It is clear that the precise
contributions of Bcl-3 to adaptive immune cell function are very complex, and despite many important
advances the immunological functions of Bcl-3 and still not fully understood. In particular, much
more work is needed to define the molecular mechanisms by which Bcl-3 regulates gene expression in
immune cells. Importantly, a more in depth understanding of the roles played by Bcl-3 in immune
pathologies could, in time, encourage the therapeutic targeting of this important regulator of NF-κB as
a way of controlling autoimmune disease and other immunopathologies.
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BCR B cell receptor
Tregs regulatory T cells
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